Kornimate/medical-research-clean huggingface dataset:
hr chest ct visual scoring, spirometry and health related quality of life in evaluating severity of ild patients

Conditions: Interstitial Lung Disease

Summary: to establish a simplified approach for assessment of severity of interstitial lung disease by evaluating the relationship between hrct findings, the clinical severity score,spirometry and quality of life.

the interstitial lung diseases are a group of parenchymal pulmonary disorders that affect the interstitium causing progressive fibrosis of lung tissue. these disorders characterized by dyspnea aggravated by exertion . this group of diseases is associated with substantial morbidity and mortality. thus, a multi-disciplinary approach including clinical, pathological, and radiological correlation is required to reach accurate assessment. the high-resolution computed tomography \[hrct\] images of the chest are considered the main platform for the diagnostic approach .high-resolution ct (hrct) scans offer the possibility of measuring disease severity more accurately and sensitively by focusing on fibrotic changes. hrct images illustrate the presence and extent of parenchymal abnormalities including: reticular opacities, ground-glass opacities, traction bronchiectasis and honeycombing. most patients with suspected ilds are likely to undergo complete pulmonary function testing. usually there is restrictive pulmonary function with decreased tlc (total lung capacity) , fvc (forced vital capacity), fev1 (forced expiratory volume in one second) and a normal or increased fev1/fvc ratio.

Eligibility criteria:
inclusion criteria: * all patients admitted at chest department or presented to our out patient clinic with clinical diagnosis of interstitial lung diseases among both sexes exclusion criteria: * patients under 18 years old. * pregnant patients. * patients with a history of previous lung resections. * presence of bronchial carcinoma or lobar consolidation. * patients contraindicated to perform pulmonary function will be excluded.
comparison of efficacy between piracetam and dimenhydrinate in patients with peripheral vertigo

Conditions: Peripheral Vertigo

Summary: this study aims to investigate efficacy of two different intravenous drugs (dimenhydrinate and piracetam) in the symptomatic management of peripheral vertigo. the patients will be randomized in two groups according to symptomatic treatment modalities: dimenhydrinate (100 mg) and piracetam (2 g) will be given in 100 cc normal saline in 30 minutes. each patient will be asked if her/his vertigo symptoms resolved or not, according to a numeric rating scale (0=no vertigo, 10=worst possible vertigo). the patient will be rate the intensity of symptoms in the following times: * numeric rating scale (1 to 10): admission * numeric rating scale (1 to 10): after the study drug (no ambulation)\* * numeric rating scale (1 to 10): after the study drug (ambulation)\* * ambulation refers to head movements or walking in the room, if applicable.


Eligibility criteria:
inclusion criteria: * presenting to emergency department with vertigo symptoms * adult patients (over 18) * agree to participate to study (understanding the study protocol and signing the informed consent form) exclusion criteria: * patients under 18 years * patients diagnosed with ischemic/hemorrhagic stroke after neuroimaging * patient diagnosed with transient ischemic attack * pregnants * patients taking any analgesics or antihistaminic drugs last 24 hours * documented or declared allergy to dimenhydrinate, piracetam or benzodiazepines * patients who do not agree to participate to the study

Keywords: vertigo dimenhydrinate piracetam
low-dose il-2( interleukin-2) treatment in sle

Conditions: Systemic Lupus Erythematosus

Summary: this clinical study will test the efficacy and safety of low dose il-2 treatment in systemic lupus erythematosus.

systemic lupus erythematosus (sle) is a chronic autoimmune syndrome affecting various organs. while available therapies, such as corticosteroids and immunosuppressive agents have improved the outcome of patients, there remains a significant unmet need for safe and more effective treatments. dysfunction of regulatory t (treg) cells has been detected in diverse autoimmune diseases, which can be promoted by interleukin-2 (il-2). we hypothesized that low-dose il-2 could be a novel therapy in active sle patients. this is a single center, uncontrolled, open-label study to assess the efficacy/safety of low dose il-2 plus standard therapy in active sle. methods: each sle patients (n=40) with scores\>=8 on the safety of estrogens in lupus erythematosus national assessment (aelena) version of the sle disease activity index (sledai) that was refractory or relaps to glucocorticoid therapy received low-dose il-2 (1 million units every other day subcutaneously (hril-2 1x 106, ip, qod) for a period of 14 days. after a 14-day rest, another cycle started) for 3-6 cycles according to the situation of the disease. the end points were safety and clinical and immunologic response. expected results: this trail will define low-dose il-2 plus standard therapy is efficacy and safety with active lupus patients, which could be relevant to the amelioration the abnormity of t help cells in sle patients.

Eligibility criteria:
inclusion criteria: * meet the american college of rheumatology criteria for the diagnosis of sle. * under standard treatment (≥ 2 months) at the time of inclusion * background treatment failed to control flares or to permit prednisone tapering * with at least one of the following manifestations: thrombocytopenia, disease-associated rash, mouth ulcer, non-infectious type of fever, active vasculitis, renal disorder(proteinuria\>0.5g/day), neuropsychiatric sle. * positive for at least one of the following laboratory tests: ana\>1:160, anti-dsdna, immunoglobulin\>20g/l, decreased c3 or c4, leukopenia\<3×10\^9/l, thrombocytopenia\<100×10\^9/l; * sle disease activity index(sledai) ≥ 8. * negative hiv test. * negative for hepatitis b and c virus. * written informed consent form. exclusion criteria: * sever chronic liver, kidney, lung or heart dysfunction; (heart failure (≥ grade iii nyha), hepatic insufficiency (transaminases\> 3n) ) * serious infection such as bacteremia, sepsis; * cancer or history of cancer cured for less than five years (except in situ carcinoma of the cervix or basocellular carcinoma); * high-dose steroid pulse therapy (\>1.5mg/kg) or iv bolus of corticosteroids in the last 2 months. * history of administration of rituximab or other biologics; * purified protein derivative (tuberculin) \>10mm * mental disorder or any other chronic illness or drug-abuse that could interfere with the ability to comply with the protocol or to give information; * inability to comply with il-2 treatment regimen.

Keywords: sle, il-2
efficacy of a web app with multimedia animations to teach therapeutic exercise in shoulder pain

Conditions: Shoulder Impingement Syndrome

Summary: the aim of this trial is to develop and evaluate a web app to teach patients about how to correctly perform a tailored program of shoulder exercises. the exercise program will be evidence based, and there will be two groups in the study, both exercising. the follow up will be of 6 months.

the web app will consist of 3d multimedia animations (video and audio) which the patient will be able to access from any device with internet connection (cell phone included). the trial will include patients with shoulder pain because of rotator cuff tendinopathy. the investigators will carry on a pilot study with 100 patients randomly distributed into two groups, with 6 months follow up. both groups will perform the same treatment, but the control group won´t use the exercise app. there will be four dependent variables: correct exercise performance, compliance degree, satisfaction with the treatment and expectations to improve with treatment. as secondary dependent variables will be analyzed pain (at rest, with movement and at night), functional disability (spadi questionnaire), and patient´s assessment of app video characteristics (usability, utility and satisfaction) and co-interventions.

Eligibility criteria:
inclusion criteria: * older than 18 with uni or bilateral shoulder region pain * being able to read and write in spanish * pain for at least 3 months * pain intensity (in rest, activity and/or at night) of at least 3/10 * two positive clinical sings at least from: neer sign, hawkins-kennedy sign, empty can or pain arc * must have and use at least 3 times/week email of their own and a device with internet connection exclusion criteria: * polyarticular or generalized pain * cognitive impairment * cancer * serious neurological disease * other shoulder pain causes * history of main trauma * sings or symptoms of cervical pain (excluding upper trapezius) or cervical radiculopathy * apprehension sing, sulcus sing * passive movement limitation (but final degree in horizontal abduction or extension) * tendon rupture in ultrasound * glenohumeral arthritis in plain radiographs or calcium bigger than 5mm

Keywords: shoulder impingement syndrome exercise web app efficacy
diet, insulin sensitivity, and postprandial metabolism

Conditions: Overweight; Obesity; Insulin Resistance

Summary: this randomized, controlled trial aims to elucidate the mechanisms by which a plant-based dietary intervention causes weight loss. using a low-fat, plant-based diet for 16 weeks, along with an untreated control for comparison, the study will measure changes in body weight, body composition, intramyocellular and/or intrahepatocellular lipid, and changes in association to body weight.

in a 16-week trial, overweight adults will be randomly assigned to two groups. changes in body weight, body composition, intramyocellular and/or intrahepatocellular lipid, and changes in association to body weight will be measured among other outcomes. the intervention group will follow a low-fat, vegan diet and will receive weekly classes and support. the control group will be asked to follow a conventional control diet. this study conducts a pilot sub-study to test the hypothesis that changes in insulin sensitivity and beta-cell function observed in response to a diet intervention correlate with changes in intramyocellular and/or intrahepatocellular lipid. another sub-study assesses the association between metabolic outcomes and gut microbiome. one additional sub-study is looking for associations between metabolic outcomes and endothelial function.

Eligibility criteria:
inclusion criteria: * men and women age ≥18 years of age * body mass index 28-40 kg/m2 exclusion criteria: 1. diabetes mellitus, type 1 or 2, history of diabetes mellitus or of any endocrine condition that would affect body weight, such as thyroid disease, pituitary abnormality, or cushing's syndrome 2. smoking during the past six months 3. alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use 4. use of recreational drugs in the past 6 months 5. use within the preceding six months of medications that affect appetite or body weight, such as estrogens or other hormones, thyroid medications, systemic steroids, antidepressants (tricyclics, monoamine oxidase inhibitors (maois), selective serotonin reuptake inhibitors (ssris), antipsychotics, lithium, anticonvulsants, appetite suppressants or other weight-loss drugs, herbs for weight loss or mood, st. john's wort, ephedra, beta blockers 6. pregnancy or intention to become pregnant during the study period 7. unstable medical or psychiatric illness 8. evidence of an eating disorder 9. likely to be disruptive in group sessions 10. already following a low-fat, vegan diet 11. lack of english fluency 12. inability to maintain current medication regimen 13. inability or unwillingness to participate in all components of the study 14. intention to follow another weight-loss method during the trial

Keywords: plant-based diet obesity insulin sensitivity intracellular lipid postprandial metabolism vegan diet beta-cell function
study to assess pharmacokinetics of accordion pill carbidopa-levodopa compared to immediate release carbidopa-levodopa in parkinson's disease patients

Conditions: Parkinson Disease

Summary: the purpose of this study is to assess the pk of ap-cd/ld given at dose of 50/500mg three times daily compared to cd/ld immediate release (sinemet) 1.5 tablets of dose of 25/100 given 5 times per day in parkinson's disease patients.

an open label, non randomized crossover phase 2 study to assess the pk of ap-cd/ld given at dose of 50/500mg three times daily compared to cd/ld immediate release (sinemet) 1.5 tablets of dose of 25/100 given 5 times per day in parkinson's disease patients. the study will have a screening period followed by an overnight stay in clinic where immediate release cd/ld (sinemet) will be administered five times, approximately every three hours. at specified intervals, blood will be drawn for pk testing. on days 2-7, subjects will be treated at home with ap cd/ld three times/day, approximately every five hours. day 8 will be overnight stay in clinic for pk study. ap cd/ld 500mg tid will be dispensed to subjects with specified timelines for pk assessment. each subject will return to clinic on day 15 for a safety followup visit.

Eligibility criteria:
inclusion criteria: 1. diagnosis of pd consistent with uk brain bank criteria 2. stable dose of levodopa/carbidopa ir for at least 4 weeks prior to entry; taking at least 4 doses of ir levodopa during waking hours, and total daily dose of at least 400mg prior to initial screening 3. stable on all anti-pd medications for 30 days prior to screening. comt inhibitors are held prior to pk studies on day 1 through day 8 exclusion criteria: 1. atypical or secondary parkinsonism 2. clinically significant cardiac, pulmonary, hepatic, or renal disease or other condition which contraindicates participation in judgement of investigator 3. severe dyskinesia as assessed by pi 4. significant cognitive impairment 5. clinically significant psychiatric illness in opinion of pi 6. history of small bowel or gastric surgery (including peg-j placement for duopa/duodopa) or bowel obstruction, diagnosis of small bowel narrowing, diagnosis of crohn's disease, frequent nausea or emesis regardless of etiology, and symptomatic gastroparesis. 7. history of gi pathology of clinical significance as determined by pi 8. allergy to study drug or yellow dye #5 (tartrazine) 9. unable to swallow large pills 10. active gerd and regular use of ppis 11. women who are pregnant or nursing or are of childbearing potential who are not willing to use a medically acceptable method of contraception
measurement of vaginal squeeze pressure in incontinent patients

Conditions: Urinary Incontinence

Summary: the patients will be submited to a vaginal squeeze pressure measurements before and after surgeries for urinary incontinence.

several techniques had been proposed for pelvic floor muscles assessment, however none of them were able to measure the two main functions of these muscles: rising and force of compression. vaginal palpation is frequently used in clinical evaluation routine and especially the modified oxford score, but some articles question the oxford scale sensitivity and its correlation with objective force contraction measurements. methods: 45 patients with urinary incontinence treated at the uroginecology ambulatory service of the hospital de clínicas de porto alegre were included. the patients had been submitted to vaginal palpation using the oxford score, assessed by a skilled physical therapist, and to the compression force measurement by means of an air filled ballonet connected to a pressure transducer. the two evaluations had been carried in the same day.

Eligibility criteria:
inclusion criteria: * stress, urge or mixed stress and urge urinary incontinence. * understanding and signing a letter of informed consent exclusion criteria: * urinary tract infection. * genitourinary surgery during the previous six months. * pregnancy or in puerperal period. * bmi \> 40

Keywords: perineometry modified oxford score pelvic muscles evaluation urinary incontinence vaginal palpation
lactic acid in the rectum and life-threatening infection

Conditions: Septic Shock

Summary: life-threatening infection impairs bloodflow to the gut, thereby causing less delivery of oxygen. this leads to increased formation of lactic acid. the investigators hypothesize, that the more serious the condition, the higher the concentration of lactic acid will be, thus relating to the risk of multiple organ failure or death.


Eligibility criteria:
inclusion criteria: * fluid resuscitated septic shock \< 24 h. exclusion criteria: * septic shock \> 24 h. * pathology in the rectum. * bleeding per rectum. * limitation of therapy. * where informed consent from relatives cannot be obtained.
a phase i trial of tecogalan sodium ( ds-4152 ) administered as an infusion twice weekly for 21 days.

Conditions: Sarcoma, Kaposi; HIV Infections

Summary: to evaluate the safety of different doses and dosing regimens of tecogalan sodium (ds-4152) and to establish the mtd at each of the different dosing schedules.

patients receive intravenous ds-4152 by infusion twice weekly for 21 days, followed by 2 weeks of rest; courses may repeat. patients undergo weekly follow-up. a punch biopsy will be obtained from patients with kaposi's sarcoma.

Eligibility criteria:
inclusion criteria patients must have: * kaposi's sarcoma plus hiv infection or metastatic solid tumor. * life expectancy of at least 12 weeks. * no symptomatic aids-defining opportunistic infection within the past 4 weeks. * recovered from toxicity of any prior anticancer therapy. exclusion criteria co-existing condition: patients with the following symptoms or conditions are excluded: * leukemia or lymphoma. * current gastrointestinal bleeding by stool guaiac. * extensive bone metastases or significant radiographic osteoporosis in patients with solid tumors. * active heart disease such as uncontrolled angina, uncompensated congestive heart failure, or dysrhythmias requiring antiarrhythmics. * acute intercurrent infection other than genital herpes. * symptomatic or known central nervous system involvement (including brain metastases) unless stable and off therapy. concurrent medication: excluded: * other anticancer therapy. * other investigational agents. patients with the following prior conditions are excluded: * history of acute or chronic gastrointestinal bleeding or inflammatory bowel disease. * history of myocardial infarction within past 6 months. prior medication: excluded: * anticancer therapy within the past 3 weeks (6 weeks for nitrosourea or mitomycin c). * investigational agents within the past 4 weeks.

Keywords: neoplasms sarcoma, kaposi acquired immunodeficiency syndrome antineoplastic agents tecogalan
participation in occupations and perception of quality of life, comparing adults with and without ptsd

Conditions: Post Traumatic Stress Disorder

Summary: this study assesses the relationship between participation and quality of life the way adults with and without post traumatic stress disorder (ptsd) experience it in everyday life. both groups will fill out questionnaires and the answers will be compared. in addition different aspects of dissociation will be taken in to consideration.

post traumatic stress disorder has been known to severely impair participation in everyday activities such as work, recreation and social participation. in turn, these impairments can diminish quality of life. however, the relationship between ptsd, functioning and quality of life remains incompletely understood. since achieving full participation in daily activities is the main goal of occupational therapy, and since quality of life is a primary treatment success measure, it is important to fully understand the relationship between ptsd, participation and quality of life. various studies show that dissociation affects different body functions that manage and monitor mental functioning. since quality of life is a subjective measure that relies on one's ability to mentally represent himself and others it is important to tack into consideration the way that dissociation affects the relationships described above. the research contains 4 questionnaires that will be filed out by the participants and the data from the questionnaires will be analyzed and compared.

Eligibility criteria:
inclusion criteria: * hebrew speaking, read and write in hebrew, have been diagnosed with ptsd following a trauma that occurred over one year before the current study. exclusion criteria: * other psychiatric disorders, cognitive or physical impairments.

Keywords: participation quality of life occupational therapy
oxygen consumption in post-stroke patients during various walking activities compared to healthy controls

Conditions: Cerebrovascular Accident

Summary: stroke is major public health issue. the investigators recommend post-stroke patients to practice physical activity. nevertheless, the recommendations are not widely respected due to the intensity of exercises. oxygen consumption is a parameter to assess the intensity of physical activity. in this sense, we want to measure the oxygen consumption during various walking tasks compared to healthy controls.

stroke is defined as an interruption of blood circulation in the brain. the treatments are in first time medical in emergency. then, the patient will start his rehabilitation with several contributors. at this time, it will recommend physical activity to patients. regardless of the all benefits of physical activity, it will help patient to avoid a second stroke. the investigators have the recommendations of the high authority of health in physical activity for stroke population. it recommends to practice around 20 to 60 minutes daily of physical activity with moderate effort intensity. oxygen consumption is a parameter of effort intensity of physical activity measured in ml o2/kg/min. currently, the investigators have the compendium of physical activity (pa). it allows us to classify pa according to effort intensity. and so, an activity with a moderate effort intensity is an activity between 3 and 5.9 metabolic equivalent task (met). note that 1 met is 3.5 ml/o2/kg. nevertheless, this compendium does not correspond to post-stroke individuals. as consequences, low intensity exercise as described in guidelines might be at a moderate intensity level for stroke survivors. hence, the investigators want to assess the oxygen consumption of post-stroke individuals during various walking tasks and compare it to healthy controls.

Eligibility criteria:
inclusion criteria: common to both groups: * age \>=18 years * able to give consent * not under guardianship or curatorship * enrolled in the french social security system specific to the cerebrovascular accident group: * stroke confirmed by brain imaging * able to walk stairs without human assistance (modified functional ambulation classification \>= 6) healthy group specific: - individuals matched to stroke individuals on age sex and bmi. exclusion criteria: cerebrovascular accident group - severe cognitive impairment (moca \< 18) common to both groups: - presence of contraindication to physical activity: unstable diabetes, unstable hypertension, unstable angina, intra-cardiac thrombus.

Keywords: stroke oxygen consumption physical activity